These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 16787193)

  • 1. Prevention of myocardial damage during coronary intervention.
    Pasceri V; Patti G; Di Sciascio G
    Cardiovasc Hematol Disord Drug Targets; 2006 Jun; 6(2):77-83. PubMed ID: 16787193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prevention of periprocedural myocardial damage in patients undergoing percutaneous coronary intervention].
    Patti G; Pasceri V; Nusca A; Di Sciascio G
    Ital Heart J Suppl; 2005 Sep; 6(9):553-60. PubMed ID: 16281714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study.
    Pasceri V; Patti G; Nusca A; Pristipino C; Richichi G; Di Sciascio G;
    Circulation; 2004 Aug; 110(6):674-8. PubMed ID: 15277322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial.
    Di Sciascio G; Patti G; Pasceri V; Gaspardone A; Colonna G; Montinaro A
    J Am Coll Cardiol; 2009 Aug; 54(6):558-65. PubMed ID: 19643320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial.
    Kim JS; Kim J; Choi D; Lee CJ; Lee SH; Ko YG; Hong MK; Kim BK; Oh SJ; Jeon DW; Yang JY; Cho JR; Lee NH; Cho YH; Cho DK; Jang Y
    JACC Cardiovasc Interv; 2010 Mar; 3(3):332-9. PubMed ID: 20298994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy.
    Patti G; Chello M; Pasceri V; Colonna D; Nusca A; Miglionico M; D'Ambrosio A; Covino E; Di Sciascio G
    J Am Coll Cardiol; 2006 Oct; 48(8):1560-6. PubMed ID: 17045888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of loading dose of atorvastatin before percutaneous coronary intervention on periprocedural myocardial injury.
    Yu XL; Zhang HJ; Ren SD; Geng J; Wu TT; Chen WQ; Ji XP; Zhong L; Ge ZM
    Coron Artery Dis; 2011 Mar; 22(1):87-91. PubMed ID: 21169815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term high-dose atorvastatin for periprocedural myocardial infarction prevention in patients with renal dysfunction.
    Toso A; Leoncini M; Maioli M; Gallopin M; Tedeschi D; Amato M; Bellandi F
    J Cardiovasc Med (Hagerstown); 2011 May; 12(5):318-21. PubMed ID: 21045713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of high reloading ROsuvastatin and Atorvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of MyocArdial periprocedural necrosis. The ROMA II trial.
    Sardella G; Lucisano L; Mancone M; Conti G; Calcagno S; Stio RE; Pennacchi M; Biondi-Zoccai G; Canali E; Fedele F
    Int J Cardiol; 2013 Oct; 168(4):3715-20. PubMed ID: 23849964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial.
    Patti G; Pasceri V; Colonna G; Miglionico M; Fischetti D; Sardella G; Montinaro A; Di Sciascio G
    J Am Coll Cardiol; 2007 Mar; 49(12):1272-8. PubMed ID: 17394957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term atorvastatin preload reduces levels of adhesion molecules in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Results from the ARMYDA-ACS CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy.
    Patti G; Chello M; Gatto L; Alfano G; Miglionico M; Covino E; Di Sciascio G
    J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):795-800. PubMed ID: 20613550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial.
    Patti G; Ricottini E; Nusca A; Colonna G; Pasceri V; D'Ambrosio A; Montinaro A; Di Sciascio G
    Am J Cardiol; 2011 Jul; 108(1):1-7. PubMed ID: 21529740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atorvastatin for reduction of myocardial damage during angioplasty trials.
    Nusca A; Melfi R; Patti G; Di Sciascio G
    J Cardiovasc Med (Hagerstown); 2010 Oct; 11(10):709-11. PubMed ID: 20815110
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of seven-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following percutaneous coronary intervention in patients receiving long-term statin therapy. A randomized study.
    Zemánek D; Branny M; Martinkovičová L; Hájek P; Malý M; Tesař D; Tomašov P; Veselka J
    Int J Cardiol; 2013 Oct; 168(3):2494-7. PubMed ID: 23597577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive statin therapy for Chinese patients with coronary artery disease undergoing percutaneous coronary intervention (ISCAP study): rationale and design.
    Liu P; Jiang J; Li J; Hong T; Zhang Y; Yu R; Jia J; Huo Y
    Catheter Cardiovasc Interv; 2012 May; 79(6):967-71. PubMed ID: 22514150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with the release of cardiac troponin T following percutaneous transluminal coronary angioplasty.
    Abbas SA; Glazier JJ; Wu AH; Dupont C; Green SF; Pearsall LA; Waters DD; McKay RG
    Clin Cardiol; 1996 Oct; 19(10):782-6. PubMed ID: 8896910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Administration of a loading dose of atorvastatin before percutaneous coronary intervention prevents inflammation and reduces myocardial injury in STEMI patients: a randomized clinical study.
    Liu HL; Yang Y; Yang SL; Luo JP; Li H; Jing LM; Shen ZQ
    Clin Ther; 2013 Mar; 35(3):261-72. PubMed ID: 23410871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distal myocardial protection with intracoronary beta blocker when added to a Gp IIb/IIIa platelet receptor blocker during percutaneous coronary intervention improves clinical outcome.
    Uretsky BF; Birnbaum Y; Osman A; Gupta R; Paniagua O; Chamoun A; Pohwani A; Lui C; Lev E; McGehee T; Kumar D; Akhtar A; Anzuini A; Schwarz ER; Wang FW
    Catheter Cardiovasc Interv; 2008 Oct; 72(4):488-97. PubMed ID: 18814223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
    Pedersen TR; Faergeman O; Kastelein JJ; Olsson AG; Tikkanen MJ; Holme I; Larsen ML; Bendiksen FS; Lindahl C; Szarek M; Tsai J;
    JAMA; 2005 Nov; 294(19):2437-45. PubMed ID: 16287954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of atorvastatin pretreatment on infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Hahn JY; Kim HJ; Choi YJ; Jo SH; Kim HJ; Lee S; Ahn KJ; Song YB; Choi JH; Choi SH; Choi YJ; Lee KH; Lee SH; Gwon HC
    Am Heart J; 2011 Dec; 162(6):1026-33. PubMed ID: 22137076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.